About: 5-year efficacy of all surface laser ablation with cross-linking (ASLA-XTRA) for the treatment of myopia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 5-year efficacy of all surface laser ablation with cross-linking (ASLA-XTRA) for the treatment of myopia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	5-year efficacy of all surface laser ablation with cross-linking (ASLA-XTRA) for the treatment of myopia
Creator	Aslanides, Ioannis Selimis, Vasileios Chen, Shihao Hafezi, Farhad Kymionis, George Lu, Nanji Maragkos, Ilias Mukherjee, Hatch
Source	PMC
abstract	BACKGROUND: The purpose of our study is to examine the long (5-year) efficacy of the all surface laser ablation (ASLA) combined with accelerated cross-linking (CXL) for the treatment of myopia without the use of mitomycin-C (MMC). METHODS: This retrospective study consisted of 202 eyes of 118 myopic (SD: 2.41, range: − 1.50 to − 12.75 D) patients (44 males, 74 females). Mean age was 28.50 years (SD: 6.45, range: 18 to 51 years) that underwent ASLA with accelerated CXL for the treatment of their myopia. RESULTS: The patients underwent routine postoperative assessment on the 1st, 3rd, 7th day and in the 1st, 3rd, 6th and 12th month, 30th month (±6 months), 4th and 5th year. The mean spherical equivalent (SEq) refractive error changed from − 6.41 ± 2.41 D preoperatively to − 0.02 ± 0.53 D at 5 years postoperatively. The haze score was 0.18, 0.25 and 0.28 at 1, 3 and 6 months postoperatively. At 12 months after the treatment, no eyes had significant corneal haze and in all the following postoperative time intervals the haze traces were gone. CONCLUSION: ASLA combined with accelerated CXL (ASLA-XTRA) appears to be safe, efficacious and offering very good refractive results. The potential additional benefits of this modality are the stabilizing effect of the refraction and its sterilization effect on the treated cornea without the potential side effects of MMC.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1186/s40662-020-00198-z
has license	cc-by
sha1sum (hex)	93a97db1e10edd7f7c66fe9a6ed2bf4b915b086f
schema:url	https://doi.org/10.1186/s40662-020-00198-z
resource representing a document's title	5-year efficacy of all surface laser ablation with cross-linking (ASLA-XTRA) for the treatment of myopia
has PubMed Central identifier	PMC7286704
schema:publication	Eye Vis (Lond)
resource representing a document's body	covid:93a97db1e10edd7f7c66fe9a6ed2bf4b915b086f#body_text
is schema:about of	named entity 'TO EXAMINE' named entity 'MITOMYCIN-C' named entity 'surface' named entity 'ASLA' named entity 'cross-linking' named entity 'retrospective study' named entity 'myopic' named entity 'myopia' named entity 'apoptosis' named entity 'excimer' named entity 'epithelium' named entity 'France' named entity 'ablation' named entity 'proparacaine' named entity 'Jacksonville' named entity 'PRK' named entity 'Johnson & Johnson' named entity 'Minneapolis' named entity 'sterilizing' named entity 'Emmetropia' named entity 'long-term' named entity 'myopic' named entity 'HPMC' named entity 'PTK' named entity 'Photorefractive keratectomy' named entity 'Irvine, CA' named entity 'epithelial' named entity 'Fantes' named entity 'cornea' named entity 'Bausch and Lomb' named entity 'epithelium' named entity 'Rochester, NY' named entity 'PRK' named entity 'logMAR' named entity 'Greece' named entity 'riboflavin' named entity 'laser ablation' named entity 'laser' named entity 'long term' named entity 'ablation' named entity 'BSS' named entity 'epithelium' named entity 'epithelial' named entity 'cornea' named entity 'PTK' named entity 'corneal fibroblasts' named entity 'Irvine, CA' named entity 'refraction' named entity 'alcohol' named entity 'debridement' named entity 'corneal surface' named entity 'ablation' named entity 'cornea' named entity 'Finland' named entity 'corneal disease' named entity 'Allergan Inc.' named entity 'eye drops' named entity 'Acuvue' named entity 'PRK' named entity 'myofibroblast' named entity 'epithelial' named entity 'ablated' named entity 'keratoconus' named entity 'visual acuity' named entity 'Allergan Inc.' named entity 'speculum' named entity 'epithelial' named entity 'Declaration of Helsinki' named entity 'ASLA' named entity 'myopic' named entity 'PRK' named entity 'treatment of patients' named entity 'post-operative' named entity 'Ofloxacin' named entity 'high myopia' named entity 'contact lens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software